Full-replicate design in two groups [General Sta­tis­tics]

posted by Mikalai  – Belarus, 2018-10-31 14:04  – Posting: # 19510
Views: 553

Dear all,
We are conducting a full replicate design study. Due to recruiting difficulties we had to split the study in two groups. It has been suggested that we should change our statistical model to model II of FDA. What risks, if any, carry on this model to our bioequivalence? Can additional factors in model artificially reduce our CV and push us out of the scaled approach to usual 125%-80% one (I am not a statistician, so my question may be statistically correct)? Should we change our usual 4-factor model?

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,302 posts in 4,102 threads, 1,317 registered users;
online 15 (1 registered, 14 guests [including 4 identified bots]).

Restlessness is discontent –
and discontent is the first necessity of progress.
Show me a thoroughly satisfied man –
and I will show you a failure.    Thomas Alva Edison

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5